Identifying Barriers to Timely Follow-up After Elevated PSA Screening: A Retrospective Analysis of a Large Healthcare System

Zhiyu Qian; Yu-Jen Chen; Precious Moman; Muhieddine Labban; Daniel Stelzl; Filippo Dagnino; Hanna Zurl; Danesha Daniels; Claudia Carranza; Kara L Watts; Alexander P Cole; Quoc-Dien Trinh

doi:10.1016/j.urology.2024.08.032

Identifying Barriers to Timely Follow-up After Elevated PSA Screening: A Retrospective Analysis of a Large Healthcare System

Urology. 2024 Aug 27:S0090-4295(24)00714-3. doi: 10.1016/j.urology.2024.08.032. Online ahead of print.

Affiliations

¹ Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
² Department of Urology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY.
³ Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. Electronic address: trinh.qd@gmail.com.

PMID: 39208942
DOI: 10.1016/j.urology.2024.08.032

Abstract

Objective: To examine elevated PSA follow-up within our system and identify areas for improvement in the timely diagnosis of prostate cancer.

Methods: We queried the Mass General Brigham's Enterprise Data Warehouse from 2018-2021, identifying patients with elevated PSA and documented time to follow-up. Timely follow-up was defined as having a urologist appointment, prostate biopsy, or prostate magnetic resonance imaging within 6 months from diagnosis. We stratified the location of elevated PSA diagnosis to academic medical centers versus community sites. Univariable and multivariable analyses were performed to identify factors impacting follow-up.

Results: We included 28,346 patients, with 50.30%, 15.02%, and 34.69% receiving timely, untimely, and no follow-up during the study period, respectively. In multivariable analysis, patients seen at academic medical centers were more likely to receive follow-up care (OR=1.39, 95%CI 1.30-1.48). In a sensitivity analysis including 2 of our largest community hospitals as part of academic medical facilities, those following up at our main sites showed even higher odds of timely follow-up (OR=1.61, 95%CI 1.51-1.73).

Conclusion: Our study observed variations in follow-up rate between our academic medical centers and community sites. This finding highlights the need for efforts to improve consistency and timeliness of prostate cancer follow-up care across all facilities. By addressing interfacility disparities, we can facilitate the delivery of timely care to all patients.